English  |  正體中文  |  简体中文  |  總筆數 :2854037  
造訪人次 :  45325813    線上人數 :  775
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

跳至:
或輸入年份:
從最近的開始 由舊到新排序

顯示項目 2290891-2290900 / 2346973 (共234698頁)
<< < 229085 229086 229087 229088 229089 229090 229091 229092 229093 229094 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2022-09-15T01:08:50Z Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone-producing thymic neuroendocrine neoplasm Chang L.-K.; Chen K.-C.; Cheng M.-F.; Chia-Chi Lin; Wang H.-P.; Sung C.-T.; Chen J.-H.; Yen R.-F.; Hsu C.-L.; Shih S.-R.
臺大學術典藏 2022-09-15T01:08:50Z Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Chia-Chi Lin; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H.
臺大學術典藏 2022-09-15T01:08:50Z Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J.
臺大學術典藏 2022-09-15T01:08:51Z Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves’ Orbitopathy Shih S.-R.; Liao S.-L.; Shih C.-W.; Wei Y.-H.; Lu T.-X.; Chou C.-H.; Yen E.-Y.; Chang Y.-C.; Chia-Chi Lin; Chi Y.-C.; Yang W.-S.; Tsai F.-C.
臺大學術典藏 2022-09-15T01:08:51Z Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study Chia-Chi Lin; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Hsu C.
臺大學術典藏 2022-09-15T01:08:51Z Clinical development of colony-stimulating factor 1 receptor (Csf1r) inhibitors Chia-Chi Lin
臺大學術典藏 2022-09-15T01:08:52Z An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer Bible K.C.; Menefee M.E.; Chia-Chi Lin; Millward M.J.; Maples W.J.; Goh B.C.; Karlin N.J.; Kane M.A.; Adkins D.R.; Molina J.R.; Donehower R.C.; Lim W.-T.; Flynn P.J.; Richardson R.L.; Traynor A.M.; Rubin J.; Lorusso P.M.; Smallridge R.C.; Burton J.K.; Suman V.J.; Kumar A.; Voss J.S.; Rumilla K.M.; Kipp B.R.; Chintakuntlawar A.V.; Harris P.; Erlichman C.
臺大學術典藏 2022-09-15T01:08:52Z Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ) Bang Y.-J.; Golan T.; Dahan L.; Fu S.; Moreno V.; Park K.; Geva R.; De Braud F.; Wainberg Z.A.; Reck M.; Goff L.; Laing N.; Mi G.; Oliveira J.M.; Wasserstrom H.; Chia-Chi Lin
臺大學術典藏 2022-09-15T01:08:53Z An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC Zhu V.W.; Lin Y.-T.; Kim D.-W.; Loong H.H.; Nagasaka M.; To H.; Ang Y.L.-E.; Ock C.-Y.; Tchekmedyian N.; Ou S.-H.I.; Syn N.L.; Reungwetwattana T.; Chia-Chi Lin; Soo R.A.
臺大學術典藏 2022-09-15T01:08:53Z PD-1 blockade in anaplastic thyroid carcinoma Capdevila J.; Wirth L.J.; Ernst T.; Aix S.P.; Chia-Chi Lin; Ramlau R.; Butler M.O.; Delord J.-P.; Gelderblom H.; Ascierto P.A.; Fasolo A.; F?hrer D.; H?tter-Kr?nke M.L.; Forde P.M.; Wrona A.; Santoro A.; Sadow P.M.; Szpakowski S.; Wu H.; Bostel G.; Faris J.; Cameron S.; Varga A.; Taylor M.

顯示項目 2290891-2290900 / 2346973 (共234698頁)
<< < 229085 229086 229087 229088 229089 229090 229091 229092 229093 229094 > >>
每頁顯示[10|25|50]項目